Kara Renita Mcmillian

Array ( [id] => 18018917 [patent_doc_number] => 20220370416 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-11-24 [patent_title] => COMPOUNDS AND METHODS FOR TARGETED DEGRADATION OF KRAS [patent_app_type] => utility [patent_app_number] => 17/223551 [patent_app_country] => US [patent_app_date] => 2021-04-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 101681 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -25 [patent_words_short_claim] => 66 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17223551 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18365864 [patent_doc_number] => 20230147455 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-05-11 [patent_title] => COMPOUNDS FOR THE PROPHYLAXIS AND/OR TREATMENT OF ACUTE RESPIRATORY DISTRESS SYNDROME [patent_app_type] => utility [patent_app_number] => 17/917175 [patent_app_country] => US [patent_app_date] => 2021-04-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7210 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 20 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17917175 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17168667 [patent_doc_number] => 20210322337 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-10-21 [patent_title] => TREATMENT OF OXIDATIVE STRESS DISORDERS INCLUDING CONTRAST NEPHROPATHY, RADIATION DAMAGE AND DISRUPTIONS IN THE FUNCTION OF RED CELLS [patent_app_type] => utility [patent_app_number] => 17/216502 [patent_app_country] => US [patent_app_date] => 2021-03-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11885 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17216502 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16946550 [patent_doc_number] => 20210205241 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-07-08 [patent_title] => BETA-HYDROXYBUTYRIC ACID COMPOSITIONSAND METHODS FOR ORAL DELIVERY OF KETONE BODIES [patent_app_type] => utility [patent_app_number] => 17/210646 [patent_app_country] => US [patent_app_date] => 2021-03-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9999 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 54 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17210646 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18581526 [patent_doc_number] => 20230263778 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-08-24 [patent_title] => ANTI-VIRAL COMPOUNDS AND METHODS FOR ADMINISTRATION THEREOF [patent_app_type] => utility [patent_app_number] => 17/905601 [patent_app_country] => US [patent_app_date] => 2021-03-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20073 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 76 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17905601 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17124375 [patent_doc_number] => 20210299143 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-09-30 [patent_title] => USE OF ANTAGONISTS TO THE NUCLEAR STEROID RECEPTOR TO INHIBIT CORONAVIRUSES [patent_app_type] => utility [patent_app_number] => 17/206719 [patent_app_country] => US [patent_app_date] => 2021-03-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8743 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 18 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17206719 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18306316 [patent_doc_number] => 20230110216 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-04-13 [patent_title] => OPHTHALMIC CHLOROPROCAINE GEL HAVING IMPROVED FUNCTIONALITY [patent_app_type] => utility [patent_app_number] => 17/911429 [patent_app_country] => US [patent_app_date] => 2021-03-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5353 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -29 [patent_words_short_claim] => 14 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17911429 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17625697 [patent_doc_number] => 20220160712 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-05-26 [patent_title] => METHODS OF TREATING RHEUMATOID ARTHRITIS AND FOR PREDICTING THE RESPONSE TO METHOTREXATE [patent_app_type] => utility [patent_app_number] => 17/198023 [patent_app_country] => US [patent_app_date] => 2021-03-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17191 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 95 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17198023 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17050625 [patent_doc_number] => 20210260059 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-08-26 [patent_title] => MDM2 INHIBITORS AND COMBINATIONS THEREOF [patent_app_type] => utility [patent_app_number] => 17/188726 [patent_app_country] => US [patent_app_date] => 2021-03-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19862 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -36 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17188726 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18320014 [patent_doc_number] => 20230118142 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-04-20 [patent_title] => AGENTS FOR USE IN THE TREATMENT OF TISSUE DAMAGE [patent_app_type] => utility [patent_app_number] => 17/904388 [patent_app_country] => US [patent_app_date] => 2021-02-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22204 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 28 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17904388 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16930773 [patent_doc_number] => 20210196662 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-07-01 [patent_title] => ORAL COMPOSITION WITH IMMUNOMODULATING EFFECT ON NATURAL KILLER CELLS [patent_app_type] => utility [patent_app_number] => 17/178370 [patent_app_country] => US [patent_app_date] => 2021-02-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6076 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17178370 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18286431 [patent_doc_number] => 20230101903 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-03-30 [patent_title] => COMPOUNDS USEFUL AS ANTI-VIRAL AGENTS [patent_app_type] => utility [patent_app_number] => 17/799055 [patent_app_country] => US [patent_app_date] => 2021-02-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7772 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17799055 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17035069 [patent_doc_number] => 20210252027 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-08-19 [patent_title] => PHARMACEUTICAL FORMULATION CONTAINING REMDESIVIR [patent_app_type] => utility [patent_app_number] => 17/168262 [patent_app_country] => US [patent_app_date] => 2021-02-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6550 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -27 [patent_words_short_claim] => 54 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17168262 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16853441 [patent_doc_number] => 20210154186 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-05-27 [patent_title] => COMPOSITIONS AND METHODS FOR INHIBITING DIHYDROOROTATE DEHYDROGENASE [patent_app_type] => utility [patent_app_number] => 17/166187 [patent_app_country] => US [patent_app_date] => 2021-02-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22367 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17166187 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18252016 [patent_doc_number] => 20230079055 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-03-16 [patent_title] => COMBINATION OF BI853520 WITH CHEMOTHERAPEUTIC DRUGS [patent_app_type] => utility [patent_app_number] => 17/797867 [patent_app_country] => US [patent_app_date] => 2021-01-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11393 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17797867 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16976130 [patent_doc_number] => 20210220367 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-07-22 [patent_title] => INHALABLE FORMULATION OF A SOLUTION CONTAINING GLYCOPYRROLATE AND OLODATEROL HYDROCHLORIDE [patent_app_type] => utility [patent_app_number] => 17/152049 [patent_app_country] => US [patent_app_date] => 2021-01-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5083 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 33 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17152049 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18427576 [patent_doc_number] => 11672775 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-06-13 [patent_title] => Treprostinil prodrugs [patent_app_type] => utility [patent_app_number] => 17/140705 [patent_app_country] => US [patent_app_date] => 2021-01-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 42 [patent_figures_cnt] => 42 [patent_no_of_words] => 23920 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 36 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17140705 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16777906 [patent_doc_number] => 20210114983 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-04-22 [patent_title] => Cathepsin C inhibitors [patent_app_type] => utility [patent_app_number] => 17/137458 [patent_app_country] => US [patent_app_date] => 2020-12-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16864 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 86 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17137458 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19209484 [patent_doc_number] => 11998518 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-06-04 [patent_title] => Acetyl-leucine or a pharmaceutically acceptable salt thereof for improved mobility and cognitive function [patent_app_type] => utility [patent_app_number] => 17/247757 [patent_app_country] => US [patent_app_date] => 2020-12-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 12314 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 127 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17247757 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18184228 [patent_doc_number] => 20230044958 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-02-09 [patent_title] => METHOD OF TREATING VIRUS INFECTION USING A TLR7 AGONIST [patent_app_type] => utility [patent_app_number] => 17/788487 [patent_app_country] => US [patent_app_date] => 2020-12-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8369 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -32 [patent_words_short_claim] => 85 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17788487 [rel_patent_id] =>[rel_patent_doc_number] =>)